• Chin-Chung Shu, Huey-Dong Wu, Ming-Chih Yu, Jann-Tay Wang, Chih-Hsin Lee, Hao-Chien Wang, Jann-Yuan Wang, Li-Na Lee, Chong-Jen Yu, Pan-Chyr Yang, and Taiwan Anti-Mycobacteria Investigation (TAMI) Group.
• Department of Traumatology, National Taiwan University Hospital, Taipei, Taiwan.
• Medicine (Baltimore). 2010 Jan 1;89(1):53-61.

AbstractThe use of high-dose inhaled corticosteroids (ICS) in patients with chronic obstructive pulmonary disease (COPD) has recently been shown to increase the incidence of pneumonia. However, to our knowledge, the impact of high-dose ICS on pulmonary tuberculosis (TB) has never been investigated. To study that impact, we conducted a retrospective study including patients aged more than 40 years old with irreversible airflow limitation between August 2000 and July 2008 in a medical center in Taiwan. Of the 36,684 patients who underwent pulmonary function testing, we included 554 patients. Among them, patients using high-dose ICS (equivalent to >500 microg/d of fluticasone) were more likely to have more severe COPD and receive oral corticosteroids than those using medium-dose, low-dose, or no ICS. Sixteen (3%) patients developed active pulmonary TB within a follow-up of 25,544 person-months. Multivariate Cox regression analysis revealed that the use of high-dose ICS, the use of 10 mg or more of prednisolone per day, and prior pulmonary TB were independent risk factors for the development of active pulmonary TB. Chest radiography and sputum smear/culture for Mycobacterium tuberculosis should be performed before initiating high-dose ICS and regularly thereafter.

21 keywords...

hide…